JP2024511597A5 - - Google Patents

Info

Publication number
JP2024511597A5
JP2024511597A5 JP2023556906A JP2023556906A JP2024511597A5 JP 2024511597 A5 JP2024511597 A5 JP 2024511597A5 JP 2023556906 A JP2023556906 A JP 2023556906A JP 2023556906 A JP2023556906 A JP 2023556906A JP 2024511597 A5 JP2024511597 A5 JP 2024511597A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
disorder
acceptable salt
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/056991 external-priority patent/WO2022195011A1/en
Publication of JP2024511597A publication Critical patent/JP2024511597A/ja
Publication of JP2024511597A5 publication Critical patent/JP2024511597A5/ja
Pending legal-status Critical Current

Links

JP2023556906A 2021-03-18 2022-03-17 シロシビンの類似体、塩、組成物、及び使用方法 Pending JP2024511597A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162749P 2021-03-18 2021-03-18
US63/162,749 2021-03-18
US202163276117P 2021-11-05 2021-11-05
US63/276,117 2021-11-05
PCT/EP2022/056991 WO2022195011A1 (en) 2021-03-18 2022-03-17 Psilocybin analogs, salts, compositions, and methods of use

Publications (2)

Publication Number Publication Date
JP2024511597A JP2024511597A (ja) 2024-03-14
JP2024511597A5 true JP2024511597A5 (enExample) 2024-11-07

Family

ID=87560439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556906A Pending JP2024511597A (ja) 2021-03-18 2022-03-17 シロシビンの類似体、塩、組成物、及び使用方法

Country Status (10)

Country Link
US (1) US20240174607A1 (enExample)
EP (1) EP4308548A1 (enExample)
JP (1) JP2024511597A (enExample)
KR (1) KR20230158511A (enExample)
AU (1) AU2026202981A1 (enExample)
BR (1) BR112023018894A2 (enExample)
CA (1) CA3212563A1 (enExample)
CO (1) CO2023013714A2 (enExample)
IL (1) IL305457A (enExample)
MX (1) MX2023010843A (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009527A (es) * 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.

Similar Documents

Publication Publication Date Title
JP2024540282A5 (enExample)
TWI228116B (en) Monoamine reuptake inhibitors for treatment of CNS disorders
JP2024522065A5 (enExample)
CN100430394C (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
JP5693814B2 (ja) 新規のヒスタミンｈ３−受容体リガンドおよびそれらの治療的応用
JP4580371B2 (ja) アゴメラチンの新規な結晶形態ｉｖ、その製造方法、およびそれを含有する薬学的組成物
CN1028024C (zh) 四唑类兴奋性氨基酸受体拮抗剂的制备方法
TW201002682A (en) Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2024533291A5 (enExample)
JP2015063529A (ja) アルホルモテロールの合成方法
JP2008106070A (ja) 新規化合物
JP2018065876A (ja) ニロチニブと選択された共結晶体を含有する多成分結晶系
JP5739415B2 (ja) （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
JP2014074067A (ja) メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形
TW201629029A (zh) 褪黑激素受體之環丙基二氫苯並呋喃調節劑
JP2002508364A (ja) セロトニン１ａ受容体に対して活性を有するアリールピペラジン
CN102595902B (zh) 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
RU2011123890A (ru) Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
WO2003024916A1 (en) Crystals of hydroxynorephedrine derivative
CN101415707B (zh) 杂双环酰胺衍生物
JP2022535850A5 (enExample)
JP2025502208A5 (enExample)
JPH08509212A (ja) ４−アリールイソインドール鎮痛薬
JP2023517729A5 (enExample)
TW200819455A (en) Pyrrolizine, indolizine and quinolizine derivatives, their preparation and their therapeutic application